139 related articles for article (PubMed ID: 23166388)
21. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
22. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
23. Metabolic Subtyping of Pheochromocytoma and Paraganglioma by
van Berkel A; Vriens D; Visser EP; Janssen MJR; Gotthardt M; Hermus ARMM; Geus-Oei LF; Timmers HJLM
J Nucl Med; 2019 Jun; 60(6):745-751. PubMed ID: 30413658
[TBL] [Abstract][Full Text] [Related]
24. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H
J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
[TBL] [Abstract][Full Text] [Related]
26. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
27. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of (18)F-FDG PET/CT metabolic parameters in metastatic differentiated thyroid cancers.
Masson-Deshayes S; Schvartz C; Dalban C; Guendouzen S; Pochart JM; Dalac A; Fieffe S; Bruna-Muraille C; Dabakuyo-Yonli TS; Papathanassiou D
Clin Nucl Med; 2015 Jun; 40(6):469-75. PubMed ID: 25899591
[TBL] [Abstract][Full Text] [Related]
29. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
30. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
[TBL] [Abstract][Full Text] [Related]
31. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E
Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478
[TBL] [Abstract][Full Text] [Related]
32. Is (18)F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience.
Inal A; Kucukoner M; Kaplan MA; Urakci Z; Nas N; Guven M; Dostbil Z; Altindag S; Isikdogan A
Rev Port Pneumol; 2013; 19(6):260-5. PubMed ID: 23993406
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
[TBL] [Abstract][Full Text] [Related]
34. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
35. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma.
Cheng NM; Fang YH; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Lin CY; Liao CT; Yen TC
J Nucl Med; 2013 Oct; 54(10):1703-9. PubMed ID: 24042030
[TBL] [Abstract][Full Text] [Related]
36. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
38. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
39. Prediction of survival and cancer recurrence using metabolic volumetric parameters measured by 18F-FDG PET/CT in patients with surgically resected rectal cancer.
Jo HJ; Kim SJ; Lee HY; Kim IJ
Clin Nucl Med; 2014 Jun; 39(6):493-7. PubMed ID: 24806602
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
Garin E; Le Jeune F; Devillers A; Cuggia M; de Lajarte-Thirouard AS; Bouriel C; Boucher E; Raoul JL
J Nucl Med; 2009 Jun; 50(6):858-64. PubMed ID: 19443590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
